Core Points - Zhejiang Apac Pharmaceutical Co., Ltd. is planning a change in control, which may lead to a change in its controlling shareholder and actual controller [1] - The company's stock will be suspended from trading starting September 29, 2025, for no more than 2 trading days [1] - As of the announcement date on October 9, 2025, the related work is still ongoing, and the company expects to remain suspended from trading for an additional 3 trading days [1] - The company will fulfill its information disclosure obligations as required and will announce and apply for resumption of trading once the matter is determined [1] - There is significant uncertainty regarding this matter, and investors are advised to be cautious [1]

证券代码：002370 证券简称：亚太药业 公告编号：2025-070 浙江亚太药业股份有限公司 关于筹划公司控制权变更进展暨继续停牌的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完 整，没有虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、公司股票（证券简称：亚太药业，证券代码：002370）自 2025 年 10 月 9 日开市起继续停牌，预计停牌时间不超过 3 个交易日。 2、公司控制权变更事项目前处于筹划阶段，尚存在重大不确定 性，敬请广大投资者注意投资风险。 司控制权变更事项的停牌公告》。 二、交易进展情况及继续停牌事项的说明 截至本公告披露日，相关各方正在积极推进本次交易的各项工作， 公司预计无法在 2025 年 10 月 9 日（星期四）上午开市起复牌。 鉴于上述事项存在不确定性，为保证公平信息披露，避免公司股 价异常波动，维护广大投资者利益，根据《深圳证券交易所上市公司 自律监管指引第 6 号——停复牌》等相关规定，经公司向深圳证券交 易所申请，公司股票（证券简称：亚太药业，证券代码：002370）自 2025 年 10 月 9 日（星期四）开市起继续停牌，预计停牌时间不超过 3 ...

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) is planning a change in control, with its major shareholder, Ningbo Fubon Holding Group, and associated parties notifying the company of this development. This is not the first time the company has considered a change in ownership, as it previously changed hands in 2021 due to financial issues stemming from a 900 million yuan acquisition that led to financial fraud allegations [1][2][4]. Group 1: Company Background and Previous Ownership Changes - Asia-Pacific Pharmaceutical was established in 1989 and went public in 2010, with a product portfolio that includes chemical drug formulations, raw materials, and drug research and development [1]. - In 2015, the company acquired 100% of Shanghai New Gaofeng for 900 million yuan, aiming to enter the high-growth pharmaceutical research service sector. However, this acquisition resulted in significant losses and financial fraud revelations [2][3]. - Following the financial scandal, the original controlling shareholders faced severe financial difficulties, leading to the acquisition of control by the "Fubon Group" through judicial auction in 2021 [3]. Group 2: Financial Performance and Current Challenges - Since the financial scandal in 2019, Asia-Pacific Pharmaceutical has reported cumulative losses exceeding 2.7 billion yuan over six and a half years, with continuous pressure on its core business [4][5]. - The company's revenue from 2019 to 2024 showed a declining trend, with total revenues of 709 million yuan, 515 million yuan, 315 million yuan, 373 million yuan, 421 million yuan, and 405 million yuan respectively. The net profit attributable to shareholders has been negative for six consecutive years [4]. - In the first half of 2025, the company reported approximately 152 million yuan in revenue, a year-on-year decrease of 31.48%, while the net profit attributable to shareholders was approximately 105 million yuan, a year-on-year increase of 1820.97%. However, the non-recurring net profit was negative, indicating core business struggles [4][5]. Group 3: Market Perception and Future Outlook - Despite weak fundamentals, Asia-Pacific Pharmaceutical's stock price surged by 85.9% in 2025, driven by overall market trends in the innovative drug sector and expectations of mergers and acquisitions in the pharmaceutical industry [6]. - The ongoing risks of delisting due to negative net profits and declining revenues highlight the urgency for the company to implement effective operational improvements under new control [5][6].

Core Viewpoint - The announcement of a potential change in control at Asia-Pacific Pharmaceutical has attracted market attention, particularly given the company's history of six consecutive years of net profit losses excluding non-recurring items [1][2]. Group 1: Financial Performance - Asia-Pacific Pharmaceutical has reported net profit losses excluding non-recurring items for six consecutive years from 2019 to 2024, with losses of -1.94 billion, -143 million, -239 million, -117 million, -68.94 million, and -28.13 million respectively [1]. - Although the company has shown a reduction in losses from 2022 to 2024, it has not yet returned to profitability [1]. Group 2: Regulatory Issues - The company has faced multiple regulatory challenges, including receiving inquiry letters from the Shenzhen Stock Exchange regarding its financial performance and cash flow from 2019 to 2022 [2]. - In April 2021, the Zhejiang Securities Regulatory Bureau issued an administrative penalty against the company for false financial reporting from 2016 to 2018, resulting in a five-year market ban for the then-chairman and general manager [2]. - The company has also received warnings and public reprimands from the Shenzhen Stock Exchange during the 2020 to 2022 period [2]. Group 3: Control Change Significance - The planned change in control is seen as a critical opportunity for the company to seek new development avenues and improve its operational status [2]. - A new controlling shareholder may bring in a new management team and strategic planning, potentially enhancing corporate governance, operational efficiency, and market expansion [2]. - However, uncertainties remain regarding whether the new controlling shareholder can effectively address existing operational issues and enhance the company's competitive edge in a challenging market [2][3].

Core Viewpoint - Three listed companies, Duori Pharmaceutical, Asia-Pacific Pharmaceutical, and Zhonghuan Environmental Protection, announced on the same day that they are planning changes in control, which may lead to changes in their controlling shareholders and actual controllers [1] Group 1: Duori Pharmaceutical - Duori Pharmaceutical's major shareholder, Tibet Jiakang Times Technology Development Co., is planning a change in control, which may lead to a change in the company's controlling shareholder and actual controller [2] - The company has experienced continuous revenue decline from 2022 to 2024, which may be a reason for the planned change in control [2] - Duori Pharmaceutical's revenue for the first half of 2025 was 107 million yuan, a year-on-year decline of 29.13%, with a net loss of 42.5 million yuan, compared to a loss of 3.27 million yuan in the same period last year [3] Group 2: Asia-Pacific Pharmaceutical - Asia-Pacific Pharmaceutical's major shareholder, Ningbo Fubang Holdings Group, is also planning a change in control, with specific transaction plans and agreements still under discussion [4] - The company has faced continuous revenue decline, with a net profit of -48.86 million yuan for the first half of 2025, a year-on-year decrease of 524.31% [5] - Asia-Pacific Pharmaceutical's revenue for the first half of 2025 was 152 million yuan, a year-on-year decrease of 31.48%, attributed to centralized procurement and intensified market competition [5]

Group 1 - The core point of the article is that Zhejiang Yatai Pharmaceutical Co., Ltd. is planning a change in company control, leading to a suspension of its stock trading [1] - The company received a notification on September 26 from its controlling shareholder, Ningbo Fubang Holding Group Co., Ltd., and associated parties regarding the control change [1] - The stock suspension will take effect on September 29, 2025, and is expected to last no more than two trading days [1]

Group 1: Control Change Announcements - Multiple A-share companies, including Duori Pharmaceutical, Asia-Pacific Pharmaceutical, and Zhonghuan Environmental Protection, announced plans for control change on September 28 [1] - Duori Pharmaceutical's controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., and actual controller Deng Yong are planning a change in control, leading to a suspension of trading from September 29, 2025, for up to two trading days [3] - Asia-Pacific Pharmaceutical received notification from its controlling shareholder, Ningbo Fubang Holdings Group Co., Ltd., regarding a potential change in control, with trading suspended from September 29, 2025, for up to two trading days [5] - Zhonghuan Environmental Protection's controlling shareholder, Zhang Bozhong, is also planning a control change, resulting in trading suspension from September 29, 2025, for up to two trading days [7] Group 2: Specific Company Details - Duori Pharmaceutical's stock was suspended at a price of 40.08, with a market capitalization of 3.206 billion [2] - Asia-Pacific Pharmaceutical's stock was suspended at a price of 5.67, with a market capitalization of 4.228 billion [4] - Zhonghuan Environmental Protection's stock was suspended at a price of 8.86, with a market capitalization of 3.761 billion [6]

（责任编辑：蔡情） 公司于2025年9月26日收到控股股东宁波富邦控股集团有限公司及一致行动人上海汉贵投资管理有 限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团队及一致行动人宋凌杰的通知，其正在筹划公 司控制权变更事项，具体交易方案、协议条款等尚需进一步论证和磋商，目前相关各方尚未签署正式交 易协议。具体情况届时以各方签订的相关正式交易协议为准。 上述事项可能导致公司控股股东及实际控制人发生变更。鉴于上述事项处于筹划阶段，尚存在重大 不确定性，为保证公平信息披露，避免公司股价异常波动，维护广大投资者利益，经公司向深圳证券交 易所申请，公司股票（证券简称：亚太药业，证券代码：002370）自2025年9月29日（星期一）开市起 停牌，预计停牌时间不超过2个交易日。 中国经济网北京9月29日讯 亚太药业(002370.SZ)昨晚披露了关于筹划公司控制权变更事项的停牌公 告。 ...

编辑 王进雨 新京报贝壳财经讯 9月28日，亚太药业公告称，公司于2025年9月26日收到控股股东宁波富邦控股集团 有限公司及一致行动人上海汉贵投资管理有限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团队 及一致行动人宋凌杰的通知，其正在筹划公司控制权变更事项，具体交易方案、协议条款等尚需进一步 论证和磋商。 为保证公平信息披露，避免公司股价异常波动，公司股票自2025年9月29日起停牌，预计停牌时间不超 过2个交易日。停牌期间，公司将根据相关事项进展情况，履行信息披露义务。 ...

Core Viewpoint - Three A-share listed companies, Duori Pharmaceutical, Zhonghuan Environmental Protection, and Yatai Pharmaceutical, announced plans for changes in control, leading to stock suspension starting September 29, 2025 [1][2]. Company Summaries Duori Pharmaceutical - The controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., and actual controller, Mr. Deng Yong, are planning a change in control, which may lead to a change in the controlling shareholder and actual controller [1]. - For the first half of the year, Duori Pharmaceutical reported revenue of approximately 107 million yuan, a year-on-year decrease of 29.13%, and a net profit attributable to shareholders of -42.5 million yuan, compared to -3.27 million yuan in the same period last year [4]. Zhonghuan Environmental Protection - The controlling shareholder, Mr. Zhang Bozhong, and his concerted party, Anhui Zhongchen Investment Holding Co., Ltd., are also planning a change in control [1]. - In the first half of the year, Zhonghuan Environmental Protection achieved total revenue of 474 million yuan, a year-on-year increase of 4.84%, and a net profit attributable to shareholders of 44.1 million yuan, up 9.69% [4]. Yatai Pharmaceutical - The controlling shareholder, Ningbo Fubang Holding Group Co., Ltd., and the management team are planning a change in control, with further discussions needed on the specific transaction plan and agreement terms [1]. - Yatai Pharmaceutical's stock price closed at 5.67 yuan per share on September 26, 2025, with a year-to-date market value increase of 85.9% [3]. - The company reported revenue of approximately 152 million yuan for the first half of the year, a year-on-year decrease of 31.48%, while the net profit attributable to shareholders was approximately 105 million yuan, a significant increase of 1820.97%. However, the non-recurring net profit was -48.86 million yuan [3][4].